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A B S T R A C T
Cytochrome P450 (CYP) 27A1 is a key enzyme in both the acidic and neutral pathways of bile acid biosynthesis
accepting cholesterol and ring-hydroxylated sterols as substrates introducing a (25R)26-hydroxy and ultimately
a (25R)26-acid group to the sterol side-chain. In human, mutations in the CYP27A1 gene are the cause of the
autosomal recessive disease cerebrotendinous xanthomatosis (CTX). Surprisingly, Cyp27a1 knockout mice
(Cyp27a1−/−) do not present a CTX phenotype despite generating a similar global pattern of sterols. Using
liquid chromatography – mass spectrometry and exploiting a charge-tagging approach for oxysterol analysis we
identified over 50 cholesterol metabolites and precursors in the brain and circulation of Cyp27a1−/− mice.
Notably, we identified (25R)26,7α- and (25S)26,7α-dihydroxy epimers of oxysterols and cholestenoic acids,
indicating the presence of an additional sterol 26-hydroxylase in mouse. Importantly, our analysis also revealed
elevated levels of 7α-hydroxycholest-4-en-3-one, which we found increased the number of oculomotor neurons
in primary mouse brain cultures. 7α-Hydroxycholest-4-en-3-one is a ligand for the pregnane X receptor (PXR),
activation of which is known to up-regulate the expression of CYP3A11, which we confirm has sterol 26-hy-
droxylase activity. This can explain the formation of (25R)26,7α- and (25S)26,7α-dihydroxy epimers of oxy-
sterols and cholestenoic acids; the acid with the former stereochemistry is a liver X receptor (LXR) ligand that
increases the number of oculomotor neurons in primary brain cultures. We hereby suggest that a lack of a motor
neuron phenotype in some CTX patients and Cyp27a1−/− mice may involve increased levels of 7α-hydro-
xycholest-4-en-3-one and activation PXR, as well as increased levels of sterol 26-hydroxylase and the production
of neuroprotective sterols capable of activating LXR.
1. Introduction
Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive
disease caused by a defective sterol (25R)26-hydroxylase enzyme, also
known as sterol 27-hydroxylase, (cytochrome P450 27A1, CYP27A1)
[1,2]. In early infancy it can present with cholestatic liver disease, in
early childhood with chronic diarrhoea and cataracts, in later child-
hood with tendon xanthomata, learning difficulties or psychiatric ill-
ness and in adult life with spastic paraparesis, a fall in IQ or frank
dementia, ataxia and/or dysarthia [1]. Patients with CTX often present
with premature atherosclerosis. CYP27A1 is the first enzyme in the
acidic pathway of bile acid biosynthesis, it oxidises the terminal carbon
of the cholesterol isooctyl side-chain first to an alcohol and
subsequently to an acid introducing R stereochemistry at C-25 [3,4]
(Fig. 1). The resulting products are (25R)26-hydroxycholesterol
(cholest-5-ene-3β,(25R)26-diol) and 3β-hydroxycholest-5-en-(25R)26-
oic acid, respectively. Note, here we adopt the systematic nomenclature
[5] recommended by the Lipid Maps consortium [6], although in much
of the literature the non-systematic names 27-hydroxycholesterol and
cholestenoic acid are adopted for these two products of CYP27A1 oxi-
dation of cholesterol. CYP27A1 is also an essential enzyme of the
neutral pathway of bile acid biosynthesis oxidising ring hydroxylated
sterols at C-26 ultimately to 25R-acids. In light of its importance in bile
acid biosynthesis, it is not surprising that sterol (25R)26-hydroxylase
deficiency leads to disease in humans. Interestingly, although the for-
mation of chenodeoxycholic acid (CDCA, 3α,7α-dihydroxy-5β-cholan-
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24-oic acid) is greatly reduced in CTX patients, biosynthesis of the other
primary bile acid, cholic acid (3α,7α,12α-trihydroxy-5β-cholan-24-oic
acid), is maintained [7]. This is achieved via the cholic acid precursor
3α,7α,12α,25-tetrahydroxy-5β-cholestan-24-one and elimination of the
terminal three carbons as acetone with the formation of cholic acid (see
Fig. 1 inset i) [8]. CTX can be treated by bile acid replacement therapy,
especially with CDCA [9] and in combination with low–density lipo-
protein (LDL)–apheresis and/or statins [10–12]. Surprisingly, knock-
out of the Cyp27a1 gene in mouse (i.e. Cyp27a1−/− mouse) does not
lead to a CTX-like phenotype, although production of bile acids is
markedly reduced [13].
In both human and mouse, CYP27A1 is expressed ubiquitously.
Human macrophages utilise CYP27A1 to generate 3β-hydroxycholest-5-
en-(25R)26-oic acid [14], offering a route for “cholesterol transport”
back to the liver. In human 7α,(25R)26-dihydroxycholest-4-en-3-one
and 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid are biosynthesised
in brain, either from cholesterol or from imported (25R)26-hydro-
xycholesterol, utilising CYP27A1, CYP7B1 and subsequently hydro-
xysteroid dehydrogenase (HSD) 3B7, and are exported from brain into
the circulation providing another route for “cholesterol transport” to
liver [15–17]. Interestingly, both 3β-hydroxycholest-5-en-(25R)26-oic
acid and 3β,7α-dihydroxycholest-5-en-(25R)26-oic acid, precursors of
7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid, are ligands to the liver
X receptors (LXRs) in neuronal cells, but the 3-oxo acid is not [18,19].
7α,(25R)26-Dihydroxycholesterol (cholest-5-ene-3β,7α,(25R)26-triol),
a precursor of 7α,(25R)26-dihydroxycholest-4-en-3-one, and its posi-
tional isomer 7α,25-dihydroxycholesterol (cholest-5-ene-3β,7α,25-
triol), have activity in the immune system as ligands to the G protein-
coupled receptor (GPCR), Epstein-Barr virus induced gene 2 (GPR183)
[20,21], while 7β,(25R)26-dihydroxycholesterol (cholest-5-ene-3β,7β,
(25R)26-triol) has been reported to be a ligand to the nuclear receptor
RORγ (RAR-related orphan receptor gamma) [22], and (25R)26-hy-
droxy-7-oxocholesterol (3β,(25R)26-dihydroxycholest-5-en-7-one) and
its isomer 25-hydroxy-7-oxocholesterol (3β,25-dihydroxycholest-5-en-
7-one) activate the hedgehog signalling pathway by binding to the
GPCR Smoothened [23].
Considering the importance of CYP27A1 in bile acid biosynthesis in
human, and the biological activity of intermediates in the acidic
pathway of bile acid synthesis [18–21], it is intriguing that the
Cyp27a1−/− mice do not show a disease phenotype. In the current
study we have investigated the profile of metabolites (> 50 sterols,
oxysterols and sterol-acids) involved in the bile acid biosynthetic
pathways in the Cyp27a1−/− mouse, concentrating on the circulation
and the brain. Our results show that the Cyp27a1−/− mouse synthe-
sises both oxysterols and cholestenoic acids with a 25S-stereochemistry.
As the 25R- and 25S-epimers of the acids are inter-convertible this
provides an additional route to the synthesis of 3β,7α-dihydroxycholest-
5-en-(25R)26-oic acid and also to bile acids. We have shown earlier that
3β,7α-dihydroxycholest-5-en-(25R)26-oic acid promotes the survival of
motor neurons [19]. Patients with CTX, but not Cyp27a1−/− mice,
may present with motor neuron dysfunction, this difference could be
explained by the presence of an additional route to synthesis of the
neuroprotective acid in mouse. We hereby show the loss of Cyp27a1 in
mice increases the levels of 7α-hydroxycholest-4-en-3-one, a pregnane
X receptor (PXR) ligand known to increase the levels of CYP3A11 [24],
resulting in expression of a murine sterol 26-hydroxylase and a pathway
to neuroprotective LXR ligands.
2. Materials and methods
2.1. Oxysterol analysis
We adopted a charge-tagging approach utilising “enzyme-assisted
derivatisation for sterol analysis” (EADSA) to enhance liquid chroma-
tography (LC) separation and mass spectrometry (MS) detection of
oxysterols [17,25,26]. This involves the stereospecific enzymatic oxi-
dation of the 3β-hydroxy-5-ene function in oxysterols (and sterols) to a
3-oxo-4-ene group and subsequent reaction with the cationic Girard P
(GP) hydrazine reagent to give charged GP-hydrazones compatible with
chromatographic separation using reversed phase solvents and high-
sensitivity analysis by electrospray ionisation (ESI)-MS and MS with
multistage fragmentation (MSn) (Fig. S1). GP-derivatives give intense
[M]+ ions in ESI and informative MS2 and MS3 spectra. As some oxy-
sterols naturally contain a oxo group they give GP-derivatives even in
the absence of oxidising enzyme. However, oxysterols containing a
native 3-oxo group are readily differentiated from oxysterols oxidised to
contain one by dividing each sample in two and performing derivati-
sation without oxidising enzyme on one portion of the sample (Fraction
B) and performing derivatisation with added enzyme on the second
portion (Fraction A), and by exploiting differentially isotope labelled
GP reagents to allow discrimination by mass (Fig. S1).
Unless otherwise indicated, materials and methods are as described
by Griffiths and co-workers [17,25,26]. Quantification was achieved
using isotope dilution mass spectrometry. No hydrolysis or solvolysis
steps were performed. 3β,7α-Dihydroxycholest-5-en-(25S)26-oic acid
was supplied as a mixture with 3β,7α-dihydroxycholest-5-en-(25R)26-
oic acid (1:3, mole:mole) as the [3α,7β-2H2] compounds by Avanti
Polar Lipids (Alabaster, AL, USA).
2.2. CYP3A4 and CYP3A11 incubations
Recombinant mouse CYP3A11 in bactosomes (Cypex Ltd., Dundee,
UK) or recombinant human 3A4 in baculosomes (Life Technologies now
Thermo Fisher Scientific) (10 pmol) was incubated with 1–10 μg of 7α-
hydroxycholesterol (cholest-5-ene-3β,7α-diol), 2 mM NADPH, 5mM
glucose-6-phosphate and 0.4 U glucose-6-dehydrogenase in 0.1M po-
tassium phosphate buffer, pH 7.4, at a final volume of 500 μL for 16 h at
37 °C. The reaction was quenched with ethyl acetate and the organic
phase dried down for oxysterol analysis as above. Negative control
experiments were performed in the absence of enzyme or NADPH.
Incubations with CYP125, a known 26-hydroxylase, were performed to
provide a positive control.
Fig. 1. Bile acid biosynthesis via the neutral, acidic, 25-hydroxylase and (25S)26-hydroxylase pathways. The 25-hydroxylase pathway is shown in inset (i), the mouse
(25S)26-hydroxylase pathway in inset (ii). R=OH in acids or SCoA in CoA thioesters. R1=H or OH. Where known, mouse enzymes are indicated in bold, CYP3A11
was found in the present work to introduce a (25S)26-hydroxy group to 7α-hydroxycholesterol as indicated by underlining of the enzyme symbol. The enzyme which
converts the (25S)26-primary alcohol to a carboxylic acid is indicated as a sterol oxidase (SO). Abbreviations: CYP, cytochrome P450; HSD, hydroxysteroid de-
hydrogenase; AKR, aldo-keto reductase; BACS, bile acyl-CoA synthetase (SLC27A5); VLCS, very long chain acyl-CoA synthetase (SLC27A2); AMACR, alpha-me-
thylacyl-CoA racemase; ACOX2, branched chain acyl-CoA oxidase 2, also called branched-chain acyl-CoA oxidase; DBP, D-bifunctional protein or multifunctional
enzyme type 2 (HSD17B4); SCPx, sterol carrier protein x. [3,4]. Metabolites of increased or decreased abundance in the Cyp27a1−/− mouse are indicated by
upward or downward arrows. Red arrows are used to indicate changes in plasma, blue arrows for brain. A solid horizontal line indicates detected but not significantly
changed. *, P < 0.05; ** P < 0.01; *** P < 0.001. P < 0.05 is considered significant. The low levels of di- and tri-hydroxycholesterols and of dihydrox-
ycholestenoic acids in brain makes it difficult to distinguish between these compounds and their 3-oxo equivalents using EADSA as their differentiation is based on
peak area difference between samples treated with and without cholesterol oxidase (see Fig. S1). Hence, for these metabolites the combined values for the two
structures are used.
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2.3. Animals
Male mouse plasma and brain samples were purchased from The
Jackson Laboratory (USA). Cyp27a1−/− mice (Cyp27a1tm1Elt, n=3,
3months of age) had no RNA or protein expression from Cyp27a1 in
liver tissue [13]. Control mice (Cyp27a1+/+, n= 3, 3months of age)
were C57BL/6J strain from the same colony.
2.4. Luciferase reporter assay
The ability of oxysterols and various cholesterol metabolites to ac-
tivate nuclear receptors i.e. PXR, constitutive androstane receptor
(CAR), LXR, farnesoid X receptor (FXR), vitamin D receptor (VDR) and
nuclear receptor related protein 1 (NURR1) was tested in luciferase
assays. Transient transfections were performed in the mouse substantia
nigra–like cell line SN4741. Cells were plated in 24-well plates (5×105
cells per well) 24 h before transfection, transfected with 1 μg of plasmid
DNA per well and complexed with 2 μL of Lipofectamine 2000
(Invitrogen). Cells were transfected with 400 ng of a PXR-, CAR-, LXR-,
FXR-, VDR-, or NURR1-responsive luciferase reporter construct and
200 ng PXR, CAR, LXRα, FXR, VDR, or NURR1 [19,24,27]. A reporter
gene expressing the Renilla luciferase (pRL-TK, Promega) was co-
transfected in all experiments as an internal control for normalization of
transfection efficiency. After a 12 h incubation, the lipid/DNA mix was
replaced with fresh 2.5% serum medium containing vehicle or appro-
priate ligand (10 μM), as specified in each experiment. Luciferase ac-
tivities were assayed 24 h later using the Dual-Luciferase Reporter
Assay System (Promega), following the manufacturer's protocol.
2.5. Primary midbrain cultures
Brains from E11.5 mouse embryos were obtained, the midbrain
region was dissected, mechanically dissociated and plated on poly-D-
lysine (150,000 cells/cm2) and grown in serum-free N2 media con-
sisting of 1:1 mixture of F12 and DMEM with 10 ng/mL insulin, 100 μg/
mL apo-transferrin, 100 μM putrescine, 20 nM progesterone, 30 nM
selenium, 6mg/mL glucose and 1mg/mL BSA. Cells were treated for
3 days in vitro (DIV) with the compounds of interest, fixed with 4% PFA
and processed for staining using appropriate antibodies. The fixed cells
were washed in PBS and blocked in 5% normal goat serum/PBS for 1 h
at room temperature. Primary antibodies were diluted in PBS (pH 7.4),
0.3% Triton X-100, 1% BSA and incubations were carried out overnight
at +4 °C or at room temperature for 2 h. The antibodies used were anti-:
Islet-1 (1:100; Developmental Studies Hybridoma Bank) and Nkx6.1
(1:200; Novus Biologicals) and appropriate secondary antibodies
(Jackson ImmunoResearch or Alexa). Cells positive for the corre-
sponding marker were counted directly at the microscope at a magni-
fication of 20×. Cells were counted in every well, in eight consecutive
fields (going from one side of the well to the other, passing through the
center), in three different wells per experiment and in three different
experiments per condition. Random pictures of the wells were taken for
every condition to document the result, and representative pictures
were subsequently selected to represent the quantitative data. Photos
were acquired with a Zeiss Axioplan microscope and a Hamamatsu
0
5
10
15
20
25
30
35
40
45
50
loretselohcyxopE-52,S42
enoid-42,3-ene-4-tselohC
24
-O
xo
ch
ol
es
te
ro
l eno-3-neid-6,4-atselohcyxordy
H-52
Ch
ol
es
ta
-5
,7
-d
ie
ne
-3
β,
25
-d
io
l
7α
-H
yd
ro
xy
ch
ol
es
ta
-4
,2
4-
di
en
-3
-o
ne
7α
-H
yd
ro
xy
de
sm
os
te
ro
l
12
α-
H
yd
ro
xy
ch
ol
es
ta
-4
,6
-d
ie
n-
3-
on
e
Ch
ol
es
ta
-5
,7
-d
ie
ne
-3
β,
12
α-
di
ol
25
-H
yd
ro
xy
vi
ta
m
in
 D
3
7α
-H
yd
ro
xy
-2
6-
no
rc
ho
le
st
-4
-e
ne
-3
,2
4-
di
on
e
22
R-
H
yd
ro
xy
ch
ol
es
te
ro
l
24
S-
H
yd
ro
xy
ch
ol
es
te
ro
l
25
-H
yd
ro
xy
ch
ol
es
te
ro
l
(2
5R
)2
6-
H
yd
ro
xy
ch
ol
es
te
ro
l
24
R-
hy
dr
ox
yc
ho
le
st
er
ol
12
α-
H
yd
ro
xy
ch
ol
es
te
ro
l
7β
-H
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
7β
-H
yd
ro
xy
ch
ol
es
te
ro
l
7-
O
xo
ch
ol
es
te
ro
l
7α
-H
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
7α
-H
yd
ro
xy
ch
ol
es
te
ro
l
Ch
ol
es
t-
4(
or
5)
-e
ne
-3
β,
6-
di
ol
7α
-H
yd
ro
xy
-5
β-
ch
ol
es
ta
n-
3-
on
e
3-
O
xo
ch
ol
es
ta
-4
,6
-d
ie
n-
26
-o
ic
 a
ci
d
3β
-H
yd
ro
xy
ch
ol
es
ta
-5
,7
-d
ie
n-
26
-o
ic
 a
ci
d
22
-H
yd
ro
xy
ch
ol
es
t-
4-
en
e-
3,
24
-d
io
ne
3β
,2
2-
D
ih
yd
ro
xy
ch
ol
es
t-
5-
en
-2
4-
on
e
3-
O
xo
ch
ol
es
t-
4-
en
-2
6-
oi
c 
ac
id
3β
-H
yd
ro
xy
ch
ol
es
t-
5-
en
-(
25
R)
26
-o
ic
 a
ci
d
24
,2
5-
D
ih
yd
ro
xy
ch
ol
es
te
ro
l
20
R,
22
R-
D
ih
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
20
R,
22
R-
D
ih
yd
ro
xy
ch
ol
es
te
ro
l
7α
,2
5-
D
ih
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
7α
,2
5-
D
ih
yd
ro
xy
ch
ol
es
te
ro
l
7α
,2
4-
D
ih
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
7α
,2
4-
D
ih
yd
ro
xy
ch
ol
es
te
ro
l
7α
,(2
5S
)2
6-
D
ih
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
7α
,(2
5 S
)2
6-
D
ih
yd
ro
xy
ch
ol
es
te
ro
l
7α
,(2
5R
)2
6-
D
ih
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
7α
,(2
5R
)2
6-
D
ih
yd
ro
xy
ch
ol
es
te
ro
l
7α
,1
2α
-D
ih
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
7α
,1
2α
-D
ih
yd
ro
xy
ch
ol
es
te
ro
l
7α
,1
2α
-D
ih
yd
ro
xy
ch
ol
es
ta
n-
3-
on
e
3β
,7
β-
D
ih
yd
ro
xy
ch
ol
es
t-
5-
en
-(
25
R/
S)
26
-o
ic
 a
ci
d
3β
,2
2,
25
-T
rih
yd
ro
xy
ch
ol
es
t-
5-
en
-2
4-
on
e
7α
-H
yd
ro
xy
-3
-o
xo
ch
ol
es
t-
4-
en
-(
25
S)
26
-o
ic
 a
ci
d
3β
,7
α-
D
ih
yd
ro
xy
ch
ol
es
t-
5-
en
-(
25
S)
26
-o
ic
 a
ci
d
7α
-H
yd
ro
xy
-3
-o
xo
ch
ol
es
t-
4-
en
-(
25
R)
26
-o
ic
 a
ci
d
3β
,7
α-
D
ih
yd
ro
xy
ch
ol
es
t-
5-
en
-(
25
R)
26
-o
ic
 a
ci
d
3β
,2
4-
D
ih
yd
ro
xy
ch
ol
es
t-
5-
en
e-
25
-m
et
ho
xi
de
7α
,1
2α
,2
5-
Tr
ih
yd
ro
xy
ch
ol
es
t-
4-
en
-3
-o
ne
Ch
ol
es
t-
5-
en
e-
3β
,7
α,
12
α,
25
-t
et
ro
l
7α
,1
2α
-D
ih
yd
ro
xy
-3
-o
xo
ch
ol
es
t-
4-
en
-(
25
S)
26
-o
ic
 a
ci
d
7α
,1
2α
-D
ih
yd
ro
xy
-3
-o
xo
ch
ol
es
t-
4-
en
-(
25
R)
26
-o
ic
 a
ci
d
To
ta
l 2
4S
,2
5-
ep
ox
yc
ho
le
st
-5
-e
ne
-3
β-
ol
x0.1
**
**
**
** ******
*
***
***
***
x0.01
**
x0.01**
*
***
*
**
**
***
**
*
***
*
x0.1**
**
**
**
***
***
***
***
ng
/m
L
Cyp27a1-/-
wt
Fig. 2. Concentrations of oxysterols and cholestenoic acids in Cyp27a1−/− (n=3) and Cyp27a1+/+ (wt, n=3) mouse plasma. No hydrolysis or solvolysis steps
were performed so the values reported are for “free” non-esterified molecules. Sterols are arranged according to mass and chromatographic order of elution of the GP-
derivative. To maintain a single y-axis magnification factors have been applied as indicated. Using the EADSA method 24S,25-epoxycholesterol isomerises to 24-
oxocholesterol, becomes hydrolysed to 24,25-dihydroxycholesterol and undergoes methanolysis to 3β,24-dihydroxycholest-5-ene-25-methoxide. The total 24S,25-
epoxycholesterol corresponds to the sum of the individual forms.
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camera C4742–95 using the Openlab software.
2.6. Statistics
For oxysterol and sterol analysis data are means ± standard de-
viation (SD), *, P < 0.05; **, P < 0.01; ***, P < 0.001 by Student's t-
test. For nuclear receptor luciferase assays data are means ± standard
error of the mean (SEM), *, P < 0.05; **, P < 0.01 by Mann-Whitney
test, compared to vehicle treatment. For the quantification of Islet-1+
cells, *, P < 0.05 by Mann-Whitney test, compared to vehicle treat-
ment.
2.7. Ethical approval
Ethical approval for mice experimentation was granted by
Stockholm Norra Djurförsöksetisks Nämnd number N154/06, N145/09,
N370/09 and N273/11.
3. Results and discussion
3.1. Analysis of plasma cholesterol and metabolite levels in the Cyp27a1−/
− mouse
3.1.1. Monohydroxycholesterols and monohydroxycholestenones
While the dominant oxysterol in both genotypes is 7α-hydro-
xycholest-4-en-3-one its level varies dramatically from
20.68 ± 6.04 ng/mL (mean ± SD) in the wild type (wt) to
1792.87 ± 634.79 ng/mL in the Cyp27a1−/− animals (Fig. 2,
Fig. 3A, Table S1). This is explained by an up-regulation of the cho-
lesterol 7α-hydroxylase enzyme (CYP7A1) in the Cyp27a1−/− ani-
mals as a consequence of reduced negative feedback by primary bile
acids on its expression [13]. The immediate product of CYP7A1 cata-
lysed hydroxylation of cholesterol, 7α-hydroxycholesterol, is subse-
quently oxidised by HSD3B7 to 7α-hydroxycholest-4-en-3-one (Fig. 1)
[3]. The level of 7α-hydroxycholesterol is also greatly elevated in
Cyp27a1−/− mouse plasma (680.78 ± 157.99 ng/mL cf.
4.05 ± 1.96 ng/mL). Sterol 12α-hydroxylase (CYP8B1) is regulated in
a similar manner to CYP7A1 in mouse [3] and thus is expected to be up-
regulated in the Cyp27a1−/−mouse. This may account for an increase
in the intensity of the peak at 8.91min in the reconstructed ion chro-
matogram (RIC) appropriate for monohydroxycholesterols (Fig. 3A),
which we annotate as 12α-hydroxycholesterol (cholest-5-ene-3β,12α-
diol, 11.47 ± 0.29 ng/mL cf. 1.62 ± 0.19 ng/mL). Note we use here
the term annotate to label a metabolite in the absence of an authentic
standard or reference spectra. 12α-Hydroxycholesterol is not commer-
cially available, but has been shown by Danielsson to be converted to
cholic acids by rats and rabbits [28]. As expected, a significant differ-
ence in the pattern of monohydroxycholesterols is the absence of (25R)
26-hydroxycholesterol in Cyp27a1−/− mouse plasma (< 0.1 ng/mL).
This oxysterol is present at a level of about 10 ng/mL in the wt mouse
plasma. Similar observations with respect to 7α-hydroxycholesterol and
(25R)26-hydroxycholesterol were made by Rosen et al. in serum and by
Honda et al. with respect to (25R)26-hydroxycholesterol in liver mi-
tochondria and to 7α-hydroxycholesterol and 7α-hydroxycholest-4-en-
3-one in liver microsomes in their studies on Cyp27a1−/− animals
[13,29]. As determined here, Mast et al. found 7α-hydroxycholest-4-en-
3-one to be much more abundant in plasma from Cyp27a1−/− mice
than wt animals [30]. Levels of brain-derived 24S-hydroxycholesterol
(cholest-5-ene-3β,24S-diol) [3] show a small but significant increase in
the Cyp27a1−/− mouse (6.34 ± 0.01 ng/mL cf. 5.40 ± 0.37 ng/mL)
perhaps as a consequence of reduced metabolism [31], as do levels of
22R-hydroxycholesterol (cholest-5-ene-3β,22R-diol, 3.28 ± 0.41 ng/
mL cf. 0.60 ± 0.02 ng/mL), the intermediate formed during side-chain
shortening in steroid hormone biosynthesis by the enzyme CYP11A1.
25-Hydroxycholesterol (cholest-5-ene-3β,25-diol) did not vary between
genotypes (< 2.5 ng/mL). This is also true of 7-oxocholesterol (3β-hy-
droxycholest-5-en-7-one,< 5 ng/mL). An interesting observation is the
presence of 24R-hydroxycholesterol (cholest-5-ene-3β,24R-diol) in
plasma of the Cyp27a1−/− mouse (1.28 ± 0.19 ng/mL), this elutes
very close to (25R)26-hydroxycholesterol, and its low level is usually
obscured by the latter oxysterol which is typically about an order of
magnitude more abundant in wt animals [32,33].
3.1.2. Dihydroxycholesterols and dihydroxycholestenones
In the wt animal, only low levels (< 1 ng/mL) of these oxysterols
are observed, the most abundant being 20R,22R-dihydroxycholesterol
(cholest-5-ene-3β,20R,22R-triol), 20R,22R-dihydroxycholest-4-en-3-
one, 7α,25-dihydroxycholest-4-en-3-one and 7α,(25R)26-dihydrox-
ycholest-4-en-3-one (Fig. 2, Fig. 3B, Table S1). The situation in the
Cyp27a1−/− mouse is very different in that high levels of 7α,12α-
dihydroxycholest-4-en-3-one (173.11 ± 53.45 ng/mL) and appreciable
levels of 7α,25-dihydroxycholest-4-en-3-one (23.86 ± 6.68 ng/mL)
are observed. These differences between genotypes are not surprising,
as both CYP7A1 and 8B1 are up-regulated in the Cyp27a1−/− mouse
as is the microsomal 25-hydroxylase CYP3A11 [34]. 7α,25-Dihydrox-
ycholest-4-en-3-one may be formed via 25-hydroxycholesterol and
subsequently 7α,25-dihydroxycholesterol, or alternatively via 7α-hy-
droxycholesterol followed by 25-hydroxylation of either 7α-hydro-
xycholesterol or 7α-hydroxycholest-4-en-3-one (Fig. S2). Cholesterol
25-hydroxylase (CH25H) is the enzyme responsible for formation of the
majority of 25-hydroxycholesterol and levels of this oxysterol do not
differ significantly between wt and Cyp27a1−/− mice, however, the
activity of CYP3A11, an alternative sterol 25-hydroxylase, is up-regu-
lated in the Cyp27a1−/− mouse [34], and could account for the hy-
droxylation at C-25 of 7α-hydroxycholesterol or 7α-hydroxycholest-4-
en-3-one to ultimately give 7α,25-dihydroxycholest-4-en-3-one. Mi-
crosomal CYP3A11 has in addition to 25-hydroxylase activity, 23R-,
24R-, 24S- and 26-hydroxylase activities [34]. In our in vitro incubation
of recombinant mouse CYP3A11 with 7α-hydroxycholesterol we ob-
served 25- and (25S)26-hydroxylation (see section 3.3.). Inspection of
the RICs appropriate to dihydroxycholesterols and dihydrox-
ycholestenones clearly reveals 7α,(25R)26-dihydroxycholest-4-en-3-
one (0.86 ± 0.19 ng/mL) in wt mouse plasma. In contrast, its epimer,
7α,(25S)26-dihydroxycholest-4-en-3-one (3.79 ± 0.56 ng/mL) is pre-
dominant in the Cyp27a1−/− mouse. Although we do not have an
authentic synthetic standard of 7α,(25S)26-dihydroxycholest-4-en-3-
one its identical MS3 spectrum to that of 7α,(25R)26-dihydroxycholest-
4-en-3-one and slightly earlier elution on reversed phase LC is entirely
compatible with our annotation. This slight shift towards early elution
is seen with other oxysterols with 25S-stereochemistry compared to
their 25R-epimers [35,36]. Only trace levels of 7α,(25S)26-dihydrox-
ycholest-4-en-3-one (< 0.1 ng/mL) are found in plasma from the wt
mice and low levels of 7α,(25R)26-dihydroxycholest-4-en-3-one
(< 0.5 ng/mL) in plasma from the Cyp27a1−/− mouse.
3.1.3. Trihydroxycholesterols and trihydroxycholestenones
In light of the elevated abundance of both 7α,12α-dihydrox-
ycholest-4-en-3-one and of 7α,25-dihydroxycholest-4-en-3-one in
plasma from the Cyp27a1−/− mouse, it might be expected that their
down-stream metabolite 7α,12α,25-trihydroxycholest-4-en-3-one
would also be elevated in plasma. As predicted, in the appropriate RIC
(Fig. 3C) a cholesterol metabolite rises in concentration from about the
detection limit (0.05 ng/mL) in the wt mice to 28.40 ± 4.52 ng/mL in
the Cyp27a1−/− animals (Fig. 2, Table S1). Although no authentic
standard was available the MS3 spectrum is entirely compatible with
the proposed 7α,12α,25-trihydroxycholest-4-en-3-one structure. It is
noteworthy that Honda et al. identified the down-stream metabolite 5β-
cholestane-3α,7α,12α,25-tetrol in liver microsomes from Cyp27a1−/
− animals [29].
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3.1.4. Hydroxycholestenoic acids
3β-Hydroxycholest-5-en-(25R)26-oic acid is present in appreciable
amounts in plasma from the wt animals (3.56 ± 1.22 ng/mL) but is
essentially absent from plasma of the Cyp27a1−/− animals (Fig. 2,
Fig. 4A, Table S1). This result is in agreement with the lack of detect-
able levels of its precursor (25R)26-hydroxycholesterol in plasma from
Cyp27a1−/− animals. No evidence for the 25S-epimer of the acid was
found in plasma of either genotype.
3.1.5. Dihydroxycholestenoic and hydroxyoxocholestenoic acids
In the wt animals we see appreciable levels of 7α-hydroxy-3-ox-
ocholest-4-en-(25R)26-oic acid (28.36 ± 7.87 ng/mL). We also see
evidence for the presence of its epimer 7α-hydroxy-3-oxocholest-4-en-
(25S)26-oic acid but at much lower levels (4.63 ± 0.65 ng/mL, Fig. 2,
Fig. 4B, Table S1). In the Cyp27a1−/− mouse we see the opposite
situation with 7α-hydroxy-3-oxocholest-4-en-(25S)26-oic acid
(9.34 ± 1.04 ng/mL) being about three times as abundant as 7α-
Fig. 3. Oxysterols in Cyp27a1−/− and Cyp27a1+/+ (wt) mouse plasma. Each chromatogram is normalised to the most intense peak at 100% relative abundance
(RA). Magnification factors are as indicated. The concentration of the indicated analyte (by retention time, Rt) is given in the right-hand corner of each chroma-
togram. Chromatograms from the oxysterol fractions treated with cholesterol oxidase (combination of sterols with a native 3-oxo group and those oxidised by
cholesterol oxidase to contain a 3-oxo group) are shown. The insets show structures of generic GP derivatives. Many oxysterols elute as twin peaks corresponding to
syn and anti conformers. (A) Monohydroxycholesterols and monohydroxycholest-4-en-3-ones. (B) Dihydroxycholesterols and dihydroxycholest-4-en-3-ones. (C)
Trihydroxycholesterols and trihydroxycholest-4-en-3-ones. (D) 3β,24-Dihydroxycholest-5-ene-25-methoxide, the methanolysis product of 24S,25-epoxycholesterol.
In (A-C) peaks are labelled with the location of the relevant hydroxy groups on the cholesterol or cholest-4-en-3-one structure. In (D) 3β,24-Dihydroxycholest-5-ene-
25-methoxide is abbreviated to 24H,25M.
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hydroxy-3-oxocholest-4-en-(25R)26-oic acid (3.23 ± 0.23 ng/mL).
This data indicates that there is a second mechanism in mouse to oxi-
dise 7α-hydroxycholest-4-en-3-one and/or 7α-hydroxycholesterol to
cholestenoic acids, independent of CYP27A1 (Fig. 1, see inset ii). Once
formed the 25S- and 25R-acids can isomerise in reactions catalysed by
α-methylacyl-CoA racemase (AMACR) following activation to their
CoA-thioesters [3,4,37]. In both the wt and Cyp27a1−/− mice low
levels of 3β,7β-dihydroxycholest-5-en-(25R/S)26-oic acid (about 1 ng/
mL) are observed. HSD3B7 is inactive towards 7β-hydroxy substrates,
requiring a 7α-hydroxy group in the substrate, hence the 3-oxo-4-ene
product is not observed.
In wt mouse 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid un-
dergoes A-ring reduction and side-chain shortening through a complex
series of reactions leading to the formation of CDCA (Fig. 1). Cytosolic
aldo-keto reductases (AKR) 1D1 and 1C4 catalyse A-ring reduction,
while side-chain shortening of the CoA thioester proceeds in the per-
oxisome catalysed by AMACR, branched chain acyl-CoA oxidase 2
(ACOX2), D-bifundtional protein (DBP, HSD17B4) and sterol carrier
protein x (SCPx) [3]. The substrate for the final step of this series is the
CoA thioester of the 24-oxo-(25R)26-carboxylic acid. With our analy-
tical method we tend to observe the carboxylic acids rather than their
CoA thioesters and β-keto acids are unstable and decompose by loss of
CO2 to the 26-nor-24-ketones [18]. As might be predicted, the con-
centration of 7α-hydroxy-26-nor-cholest-4-ene-3,24-dione is reduced
from 1.33 ± 0.14 ng/mL in the wt mouse to 0.18 ± 0.05 ng/mL in the
Cyp27a1−/− mouse. We do not have an authentic standard for 7α-
hydroxy-26-nor-cholest-4-ene-3,24-dione, but retention time and MS3
spectrum are compatible with the proposed structure.
Fig. 3. (continued)
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3.1.6. Trihydroxycholestenoic and dihydroxyoxocholestenoic acids
The RICs appropriate to trihydroxycholestenoic and dihydroxyox-
ocholestenoic acids are shown in Fig. 4C. Each of the four labelled
peaks gives essentially an identical MS3 spectrum. Considering wt
plasma first, we assign the peaks at 3.69 and 4.27min to the syn and
anti forms of GP-derivatised 7α,12α-dihydroxy-3-oxocholest-4-en-
(25R)26-oic acid (3.39 ± 1.46 ng/mL). In plasma from the
Cyp27a1−/− mice the intensities of these two peaks are reduced
(1.94 ± 0.18 ng/mL), although not significantly, however, two earlier
eluting peaks at 3.53 and 4.06min are enhanced which we assign to the
syn and anti forms of the 7α,12α-dihydroxy-3-oxocholest-4-en-(25S)26-
oic acid (7.79 ± 0.88 ng/mL). These peaks are only minor in plasma
from the wt animals (0.63 ± 0.31 ng/mL). The identification of the
25R- and 25S-epimers was confirmed in studies of the AMACR
Fig. 4. Cholestenoic acids in Cyp27a1−/− and Cyp27a1+/+ (wt) mouse plasma. Each chromatogram is normalised to the most intense peak at 100% RA.
Magnification factors are as indicated. The concentration of the indicated analyte (by Rt) is given in the right-hand corner of each chromatogram. Chromatograms
from the oxysterol fractions treated with cholesterol oxidase (combination of sterols with a native 3-oxo group and those oxidised by cholesterol oxidase to contain a 3-
oxo group) are shown in (A)–(B). The insets show structures of generic GP derivatives. Many cholestenoic acids elute as twin peaks corresponding to syn and anti
conformers. (A) 3β-Hydroxychest-5-enoic and 3-oxocholest-4-enoic acids, and dihydroxycholestenones and hydroxycholestenediones. (B) Dihydroxycholestenoic and
hydroxyoxocholestenoic acids. (C) Dihydroxyoxocholestenoic acids. Abbreviations: 3β-HCA, 3β-hydroxycholest-5-en-(25R)26-oic; 7αH,3O-CA(25R or S), 7α-hy-
droxy-3-oxocholest-4-en-(25R or S)26-oic; 3β,7β-diHCA, 3β,7β-dihydroxycholest-5-en-26-oic; and 7α,12α-diH,3O-CA(25R or S), 7α,12α-dihydroxy-3-oxocholest-4-
en-(25R or S)26-oic acids. The peaks at 7.30min and 7.31min in (A) are annotated to a combination of 3β,22-dihydroxycholest-5-en-24-one and 22-hydroxycholest-
4-ene-3,24-dione. The peaks at 4.90min and 4.87min in (B) are annotated to 3β,22,25-trihydroxycholest-5-en-24-one.
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knockout mouse [32]. In combination, this data reinforces the notion
that there is an additional route to introducing a carboxylic acid group
to the terminal carbon of the sterol isooctyl side-chain in mouse besides
that provided CYP27A1 (Fig. 1, insert ii). Honda et al. have proposed
that mouse hepatic CYP3A11 has 26-hydroxylase activity towards 5β-
cholestane-3α,7α,12α-triol and 5β-cholestane-3α,7α,12α,25-tetrol and
that the expression of this enzyme is up-regulated in the Cyp27a1−/−
mouse [34]. Our data suggest that this, and/or another enzyme, also
oxidises 7α,12α-dihydroxycholest-4-en-3-one at the C-26 position to
the (25S)26-sterol acid. Once formed the (25S)26- and (25R)26-sterol
acids are inter-convertible [37].
3.1.7. 24S,25-Epoxycholesterol
Unlike other oxysterols, 24S,25-epoxycholesterol (3β-hydro-
xycholest-5-en-24S,25-epoxide) is formed through a shunt of the me-
valonate pathway, specifically the Bloch arm of the pathway (Fig. S3).
In the shunt pathway squalene epoxidase (SQLE) introduces two oxygen
atoms into squalene rather than one and the enzyme 24-dehy-
drocholesterol reductase (DHCR24) is not involved. We observe low
levels of 24S,25-epoxycholesterol (< 1 ng/mL) in plasma of the wt
animal, but significantly higher amounts in plasma of the Cyp27a1−/
− animals (4.66 ± 0.72 ng/mL, Figs. 2, 3D, Table S1). Rosen et al.
found that hepatic levels of HMG-CoA reductase (Hmgcr) mRNA are 2–3
fold higher in the Cyp27a1−/− animals than wt [13], while Båvner
et al. found elevated levels of lathosterol, a marker of cholesterol
synthesis, in liver of Cyp27a1−/− mice [38]. Thus, our data supports
the concept of an enhanced flow of metabolites through the mevalonate
pathway in Cyp27a1−/− mice and an increase in cholesterol bio-
synthesis. An alternative route to 24S,25-epoxycholesterol has recently
been suggested by Goyal et al., who show that the human cholesterol
24S-hydroxylase (CYP46A1) enzyme can oxidise desmosterol (cholesta-
5,24-dien-3β-ol) to the 24S,25-epoxide (Fig. S3) [39]. An elevation of
24S,25-epoxycholesterol formed via this route would similarly be
compatible with an increase in flow of metabolites through the meva-
lonate pathway. An alternative explanation could be that knockout of
Cyp27a1 removes a route for epoxide metabolism.
3.1.8. Other oxysterols
A number of other oxysterols were found which differ in abundance
between the two mouse genotypes. While 7α-hydroxydesmosterol (cho-
lesta-5,24-diene-3β,7α-diol, 0.29 ± 0.34 ng/mL) and its down-stream
metabolite 7α-hydroxycholesta-4,24-dien-3-one (2.59 ± 0.95 ng/mL)
are presumptively identified (by retention time and MS3 spectra in the
absence of authentic standards) in plasma from the Cyp27a1−/− mice,
they are absent from the wt plasma (<0.1 ng/mL) (Fig. 2, Fig. S4A,
Table S1). This can be explained by the up-regulated CYP7A1 enzyme
using desmosterol as a substrate in the Cyp27a1−/− mouse (Fig. S2,
inset i). In plasma from the Cyp27a1−/− mouse, at least two other
metabolites with the same mass as 7α-hydroxycholesta-4,24-dien-3-one
are observed, but are absent in the wt plasma. Based on MS3 spectra,
these are annotated as 25-hydroxycholesta-4,6-dien-3-one
(10.03 ± 2.63 ng/mL) and 12α-hydroxycholesta-4,6-dien-3-one
(101.14 ± 28.42 ng/mL). Båvner et al. have proposed the formation of
cholesta-4,6-dien-3-one from 7α-hydroxycholest-4-en-3-one in
Cyp27a1−/− mice (Fig. S2, inset ii) [38]. The diene may then act as a
substrate for up-regulated CYP8B1 or CYP3A11 to introduce hydroxy
groups at C-12α or C-25, respectively. Alternatively, the microsomal
enzyme, which dehydrates 7α-hydroxycholest-4-en-3-one to cholesta-
4,6-dien-3-one [40] may similarly dehydrate 7α,12α-dihydroxycholest-
4-en-3-one and 7α,25-dihydroxycholest-4-en-3-one to the respective 4,6-
dienes. 7α-Hydroxycholest-4-en-3-one is also a substrate for Δ4–3-ox-
osteroid 5β-reductase (AKR1D1), which reduces the 4–5-double bond
giving 7α-hydroxy-5β-cholestan-3-one [3]. When a RIC is plotted for the
appropriate m/z from Cyp27a1−/− plasma (Fig. S4B) a peak is ob-
served which we annotate to 7α-hydroxy-5β-cholestan-3-one
(10.35 ± 1.59 ng/mL, Fig. 2, Table S1). This peak is absent in analysis
of wt plasma. DeBarber et al., also using a LC-MS method with deriva-
tisation, similarly found a metabolite of elevated abundance in
Cyp27a1−/− mouse plasma, which was annotated to 7α-hydroxy-5β-
cholestan-3-one [41]. The enzyme AKR1D1 will similarly reduce 7α,12α-
dihydroxycholest-4-en-3-one and probably 7α,25-dihydroxycholest-4-en-
3-one to their 5β-cholestan-3-one equivalents. The RIC of the appropriate
m/z 552.4160 reveals two peaks (Fig. S4C), one of which has a retention
Fig. 4. (continued)
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time compatible with 7α,12α-dihydroxy-5β-cholestane-3-one
(35.49 ± 8.20 ng/mL). This peak is absent when wt plasma is analysed.
3.1.9. 25-Hydroxyvitamin D3
In their initial study, Rosen et al. using a radioimmunoassay found
that Cyp27a1−/− mice had somewhat higher serum concentrations of
25-hydroxyvitamin D3 (9,10-secocholesta-5,7,10(19)-triene-3β,25-diol)
than wt animals [13]. In the present study we similarly find an elevated
level of this secosterol in Cyp27a1−/− mouse plasma
(9.66 ± 7.98 ng/mL cf. 2.80 ± 1.17 ng/mL) but the difference with
wt is not significant (Fig. 2, Fig. S4A, Table S1).
3.1.10. Cholesterol, desmosterol, 7(or8)-dehydrocholesterol, 7(or8)-
dehydrodesmosterol, cholestenone and cholestanol
The concentration of non-esterified cholesterol in plasma of the
Cyp27a1−/− mouse (242.79 ± 28.39 μg/mL) is similar to that of the
wt (223.22 ± 7.23 μg/mL, Figs. S5A, S6A, Table S1). Rosen et al. also
found this to be true for total cholesterol [13], although Båvner et al.
found a small but significant fall in cholesterol levels in the male
Cyp27a1−/− mouse [38]. Surprisingly, we find a significant reduction
in desmosterol levels in the Cyp27a1−/− mouse compared to the wt
(0.14 ± 0.03 μg/mL cf. 0.28 ± 0.05 μg/mL). This would argue against
an up-regulation of the Bloch arm of the mevalonate pathway suggested
above (section 3.1.7) to explain the increase in 24S,25-epoxycholesterol
in plasma from the Cyp27a1−/− mouse. However, an alternative ex-
planation for a fall in desmosterol levels is an increase in its metabolism
in the Cyp27a1−/− mouse, i.e. through 7α-hydroxylation by up-
regulated CYP7A1. Båvner et al. found increased lathosterol levels in
liver of the Cyp27a1−/− mouse indicating up-regulation of the Kan-
dutsch-Russell arm of the mevalonate pathway [38]. This is supported
by our finding of elevated levels of 8(9)-dehydrocholesterol (cholesta-
5,8(9)-dien-3β-ol) in the Cyp27a1−/− mouse (0.64 ± 0.21 μg/mL cf.
0.07 ± 0.09 μg/mL). 8(9)-Dehydrocholesterol is an enzymatically
formed isomer of 7-dehydrocholesterol (cholesta-5,7-dien-3β-ol, Fig.
S3) [42]. Two other sterols detected in plasma were cholesta-4,6-dien-
3-one and cholest-4-en-3-one. Neither showed a significant change in
concentration in plasma for the two genotypes, although an increase in
cholesta-4,6-dien-3-one in the Cyp27a1−/− animal tended towards
significance (0.21 ± 0.05 μg/mL cf. 0.07 ± 0.08 μg/mL, P=0.06).
Likewise, DeBarber et al. also found higher levels of cholesta-4,6-dien-
3-one in plasma of the Cyp27a1−/−mouse than in the wt [41]. A final
metabolite detected in both Cyp27a1−/− and wt mice was a choles-
tatrien-3β-ol. The MS3 spectrum suggests that this corresponds to 7-
dehydrodesmosterol (cholesta-5,7,24-trien-3β-ol) or its Δ8 isomer. This
metabolite is more abundant in Cyp27a1−/− plasma than in the wt
(0.06 ± 0.02 μg/mL cf. 0.02 ± 0.01 μg/mL). 7-Dehydrodesmosterol is
the immediate precursor of desmosterol in the Bloch pathway. We were
unable to detect cholestanol (5α-cholestan-3β-ol) in plasma from either
mouse genotypes. In studies by others, cholestanol has been found to be
elevated in the Cyp27a1−/− mouse [30]. Our inability to detect
cholestanol in this study is probably a dynamic range issue as a con-
sequence of its low abundance in comparison to cholesterol which
elutes close by in our LC system.
3.2. Analysis of brain cholesterol and metabolite levels in the Cyp27a1−/
− mouse
As humans with CTX can show spastic paraparesis, a fall in IQ or
frank dementia and ataxia we next examined the oxysterol and sterol
profile of brain from Cyp27a1−/− mice and wt controls.
3.2.1. Monohydroxycholesterols and monohydroxycholestenones
The dominant oxysterol in both Cyp27a1−/− and wt mouse brain
is 24S-hydroxycholesterol and the levels are approximately equal at
about 25 ng/mg (Figs. 5A & B, 6, Fig. S7 Table S1). Similarly, Ali et al.
also found approximately equal levels of 24S-hydroxycholesterol in
brain cortex of the two genotypes [43], however, Mast et al. found
lower levels of 24S-hydroxycholesterol in whole brain and in cere-
bellum of the Cyp27a1−/−mouse than wt [30]. While here, and in the
study by Ali et al., measurements are in ng/mg, Mast et al. used the
units pmol/mg protein [30,43]. Low levels of the 24R-epimer are also
observed in each genotype (< 1 ng/mg). Only trace amounts of (25R)
26-hydroxycholesterol are observed in the wt mice (≤0.1 ng/mg), but
as expected this oxysterol is essentially absent in the Cyp27a1−/−
mice (≤0.01 ng/mg). It is difficult to resolve 24R-hydroxycholesterol
from (25R)26-hydroxycholesterol even using an extended gradient
(Fig. 5B) [35]. In contrast to (25R)26-hydroxycholesterol, there is an
increase in the level of 7α-hydroxycholesterol in the brain of
Cyp27a1−/− mice compared to controls (2.49 ± 0.35 ng/mg cf.
0.04 ± 0.01 ng/mg). This is also seen for 7α-hydroxycholest-4-en-3-
one (0.06 ± 0.01 ng/mg cf.< 0.01 ng/mg), 7-oxocholesterol
(0.03 ± 0.00 ng/mg cf. 0.00 ± 0.00 ng/mg), 7β-hydroxycholesterol
(cholest-5-ene-3β,7β-diol, 0.34 ± 0.03 ng/mg cf. 0.04 ± 0.01 ng/mg)
and 6β-hydroxycholesterol (cholest-4-ene-3β,6β-diol, 0.71 ± 0.17 ng/
mg cf. 0.04 ± 0.00 ng/mg). 6β-Hydroxycholesterol is formed in our
derivatisation procedure by hydrolysis of cholestane-3β,5α,6β-triol, a
metabolite formed from both 5α- and 5β-epimers of 5,6-epox-
ycholesterol (3β-hydroxycholestan-5,6-epoxide) in a reaction catalysed
by cholesterol epoxide hydrolase [44]. Cholestane-3β,5α,6β-triol is
known to be converted to the bile acid 3β,5α,6β-trihydroxycholanoic
acid in a pathway involving CYP27A1 [45–47]. The absence of
CYP27A1 in brain of the Cyp27a1−/− mouse may explain the eleva-
tion of the cholestane-3β,5α,6β-triol surrogate, 6β-hydroxycholesterol,
observed here. As CYP7A1, the enzyme that generates 7α-hydro-
xycholesterol, is not reportedly expressed in brain [3], it is likely that
the origin of 7α-hydroxycholesterol and 7α-hydroxycholest-4-en-3-one
is extracerebral. In a previous study of the Cyp27a1−/− mouse, Rosen
et al. also found elevated levels of 7α-hydroxycholesterol in brain [13]
and Båvner et al. suggested that this oxysterol crosses the blood brain
barrier (BBB) from the circulation to brain [38]. The parallel increase in
abundance of 7-oxocholesterol and 7β-hydroxycholesterol with 7α-
hydroxycholesterol and 7α-hydroxycholest-4-en-3-one in brain suggests
that the former two oxysterols may be related to the latter two in terms
of biosynthesis and/or metabolism. This concept is supported by recent
publications by Shinkyo et al. [48] and Björkhem et al. [49] who both
showed that human CYP7A1 can convert 7-dehydrocholesterol to 7-
oxocholesterol, while Larssen et al. showed that 7-oxocholesterol and
7β-hydroxycholesterol are inter-convertible in man [50], the enzyme
catalysing this reaction in man and in mouse being 11β-hydroxysteroid
dehydrogenase type 1 (HSD11B1) [51]. All four 7-oxidised forms of
cholesterol are known to be metabolised by CYP27A1 and the absence
of this enzyme in Cyp27a1−/− mouse brain is the likely driver to their
increase seen here [47]. As in plasma, we observe a metabolite which
we annotate as 12α-hydroxycholesterol in brain of the Cyp27a1−/−
mouse, but unlike in plasma its level does not differ significantly be-
tween the two genotypes (0.10 ± 0.05 ng/mg cf. 0.05 ± 0.01 ng/mg).
3.2.2. Dihydroxycholesterols and dihydroxycholestenones
The low levels of these metabolites made it difficult to distinguish
between dihydroxycholesterols and dihydroxycholestenones, as using
EADSA their differentiation is based on peak area difference between
samples treated with and without cholesterol oxidase. Hence, for these
metabolites the combined values for the two structures are given, and
for simplicity we just refer to them as dihydroxycholestenones. The
pattern of dihydroxycholestenones in brain of both the Cyp27a1−/−
and wt mice is complex (Fig. 5C). In the Cyp27a1−/− and wt mice we
observe both 7α,25- and 7α,24-dihydroxycholest-4-en-3-ones. In the
Cyp27a1−/− animals we see an elevation in the levels of these me-
tabolites compared to wt. As the first peaks of the syn/anti pairs of both
oxysterols almost co-elute we measured the combined amount for the
two oxysterols (Figs. 5C, 6, Table S1). This gave a value of
0.12 ± 0.01 ng/mg in the Cyp27a1−/− animals compared with
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0.03 ± 0.00 ng/mg in the wt. As in plasma, we find 7α,(25S)26-di-
hydroxycholest-4-en-3-one in brain of the Cyp 27a1−/− mouse
(0.04 ± 0.00 ng/mg) and also traces of the 25R epimer
(0.01 ± 0.00 ng/mg). In the wt animal the 25R epimer is present at
trace levels (0.01 ± 0.00 ng/mg) while the 25S isomer is essentially
absent (< 0.01 ng/mg). The exact origin of these 7α,26-dihydroxy
metabolites in brain is not clear; a possible origin in the Cyp27a1−/−
mice is that they formed in brain by side-chain hydroxylation of
imported 7α-hydroxycholesterol or 7α-hydroxycholest-4-en-3-one by
up-regulated CYP3A11 (Fig. 1, inset ii), which is reported to be ex-
pressed in brain [52]. Alternatively, CYP46A1, which is abundantly
expressed in brain has 25-hydroxylase, (25R)26-hydroxylase as well as
24S-hydroxylase activity to cholesterol and can also use 7α-hydro-
xycholesterol as a substrate and thus may account for some of the di-
hydroxy metabolites found in the two genotypes (Fig. S7) [53]. There is
likely to be also some direct 7α-hydroxylation of side-chain
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12α-hydroxycholestadien-3-one.
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hydroxylated substrates by CYP7B1 accounting for 7α,(25R)26-dihy-
droxy metabolites in the wt brain. CYP7B1 is an oxysterol 7α-hydro-
xylase which is expressed in brain and 7α-hydroxylates both 25- and
(25R)26-hydroxycholesterols but has only minor activity towards 24S-
hydroxycholesterol [3,54], however, this latter substrate is greatly
dominating in brain, and its hydroxylation by CYP7B1 may account for
the observation of some of the 7α-hydroxy metabolite. CYP39A1, the
oxysterol 7α-hydroxylase which acts on 24S-hydroxycholesterol is ex-
pressed in many tissues. The Cyp39a1 gene is reported to be expressed
in the somatosensory cortex of adult mouse brain [55]. The major di-
hydroxycholestenone in Cyp27a1−/− brain is 7α,12α-dihydrox-
ycholest-4-en-3-one, this oxysterol is not detected in wt brain
(0.50 ± 0.17 ng/mg cf.< 0.01 ng/mg). Its high level in plasma sug-
gests it may be imported from the circulation into brain.
3.2.3. Trihydroxycholesterols and trihydroxycholestenones
As above, combined values for these two generic structures were
recorded, and for simplicity we just refer to them as trihydrox-
ycholestenones. As in plasma from the Cyp27a1−/− mice we see a
trihydroxycholestenone in brain, which we annotate with the structure
7α,12α,25-trihydroxycholest-4-en-3-one (0.24 ± 0.02 ng/mg, Fig. 5D).
There is no evidence for this molecule in wt brain (Fig. 6, Table S1).
3.2.4. Cholestenoic acids
As reported earlier only trace levels of 3β-hydroxycholest-5-en-
(25R)26-oic and 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid are
observed in the wt animals (about 0.01 ng/mg, Figs. 6, 7A & B, Table
S1) [19], while only 7α-hydroxy-3-oxocholest-4-en-(25S)26-oic is ob-
served in brain of the Cyp27a1−/− animals at the limit of detection
Fig. 5. (continued)
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(0.01 ng/mg). As above, the values for 7α-hydroxy-3-oxocholest-4-en-
(25R)26-oic and its 25S-epimer also include a contribution from the
3β,7α-dihydroxy-acids.
3.2.5. 24S,25-Epoxycholesterol
We have reported earlier that the level of 24S,25-epoxycholesterol
is reduced in brain of Cyp27a1−/− mice (0.92 ± 0.05 ng/mg, cf.
1.32 ± 0.07 ng/mg, Figs. 5E, 6, Table S1) [56]. This is in contrast to
the situation in plasma, but is compatible with reduced cholesterol
biosynthesis through the Bloch arm of the cholesterol biosynthesis
pathway as observed by Ali et al. who found reduced desmosterol levels
in cortex of brain of Cyp27a1−/− animals [43]. We also find reduced
levels of desmosterol in whole brain of the Cyp27a1−/− mouse (see
section 3.2.7). The current data also supports the recent report of Goyal
et al. that shows that 24S,25-epoxycholesterol can be formed from
desmosterol in a reaction catalysed by CYP46A1 (Fig. S3) [39].
3.2.6. Other oxysterols
The level of 7α-hydroxydesmosterol is elevated in brain of the
Cyp27a1−/− mice (0.03 ± 0.00 ng/mg cf. 0.01 ± 0.00 ng/mg,
Figs. 5F, 6, Table S1). The oxysterols annotated as 12α-hydro-
xycholesta-4,6-dien-3-one (0.07 ± 0.06 ng/mg cf.< 0.01 ng/mg) and
7α-hydroxy-5β-cholestan-3-one (0.21 ± 0.21 ng/mg cf.< 0.01 ng/
mg) are also elevated in the Cyp27a1−/− mouse but not to sig-
nificance.
Fig. 5. (continued)
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3.2.7. Cholesterol, desmosterol, 7(or 8)-dehydrocholesterol, cholestenone
and cholestadienone
As found by others [30,38,43], and as we reported earlier, the
cholesterol levels in brain of the Cyp27a1−/− and the wt mouse are
essentially the same (16.98 ± 0.96 μg/mg cf. 16.90 ± 0.29 μg/mg,
Figs. S6B, S8A, Table S1) [56], while the desmosterol level in brain of
the Cyp27a1−/− mice is lower than in the wt (0.04 ± 0.00 μg/mg cf.
0.06 ± 0.00 μg/mg), however, the level of 8(9)-dehydrocholesterol is
higher in the Cyp27a1−/− mice than wt (0.05 ± 0.00 μg/mg cf.
0.01 ± 0.00 μg/mg, Fig. S8C). 8(9)-Dehydrocholesterol is formed from
7-dehydrocholesterol through enzymatic isomerisation (Fig. S3) [42].
This data agrees with that of Båvner et al., Ali et al. and Mast et al. who
suggested that the Kandutsch-Russell pathway is up-regulated in brain
of the Cyp27a1−/− mouse while the Bloch pathway is down-regulated
or not changed [30,38,43]. We also observe enhanced amounts of
cholest-4-en-3-one (1.30 ± 0.82 μg/mg cf. 0.17 ± 0.06 μg/mg) in
brain of the Cyp27a1−/− mice compared to wt mice. We did not
quantify cholesta-4,6-dien-3-one but it gave a stronger signal in chro-
matograms from the Cyp27a1−/− mouse than the wt. It has been
suggested that these two sterols are involved in the formation of cho-
lestanol in CTX. Although we failed to detect cholestanol in our study,
probably on account of the limited dynamic range of our LC-MS method
and saturating amounts of cholesterol, Båvner et al. and Mast et al. have
found elevated levels of cholestanol by GC–MS in Cyp27a1−/− mouse
brain [30,38]. Cholestanol is suggested to be formed via two mechan-
isms, one involving dehydrogenation of cholesterol to cholest-4-en-3-
one by a 3β-hydroxy-Δ5-dehydrogenase (other than HSD3B7) followed
by two reductive steps, and the other from 7α-hydroxycholest-4-en-3-
one by dehydration followed by saturation of the 6–7 double bond to
give cholest-4-en-3-one (Fig. S3, inset i) [57]. The observation of both
cholesta-4,6-dien-3-one and cholest-4-en-3-one suggests that the second
pathway is utilised in Cyp27a1−/− brain, at least to some extent.
3.3. Enzyme activity of CYP3A11 and CYP3A4
In a previous study Honda et al. showed that hepatic microsomal
23-, 24-, 25- and 26-hydroxylations of 5β-cholestane-3β,7α,12α-triol
and 23R-, 24R-, 24S- and 27-hydroxylations of 5β-cholestane-
3β,7α,12α,25-tetrol were catalysed by CYP3A enzymes, CYP3A4 in
man and predominantly by CYP3A11 in mouse [34]. Here we per-
formed a preliminary study to investigate whether these two enzymes
also had activity towards 7α-hydroxycholesterol, the primary product
of CYP7A1 catalysed hydroxylation of cholesterol. We found that re-
combinant human CYP3A4 hydroxylates 7α-hydroxycholesterol pre-
dominantly to 7α,25-dihydroxycholesterol and to a minor extent to 7α,
(25S)26-dihydroxycholesterol. Recombinant CYP3A11 generates minor
quantities of both 7α,(25S)26-dihydroxycholesterol and 7α,25-dihy-
droxycholesterol. Reducing the substrate concentration from 50 μM
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Fig. 6. Concentrations of oxysterols and cholestenoic acids in Cyp27a1−/− (n=3) and Cyp27a1+/+ (wt, n= 3) mouse brain. No hydrolysis or solvolysis steps
were performed so the values reported are for “free” non-esterified molecules. Sterols are arranged according to mass and chromatographic order of elution of the GP-
derivative. To maintain a single y-axis magnification factors have been applied as indicated. The low levels of di- and tri-hydroxycholesterols and of dihydrox-
ycholestenoic acids in brain made it difficult to distinguish between these compounds and their 3-oxo equivalents using EADSA as their differentiation is based on
peak area difference between samples treated with and without cholesterol oxidase. Hence, for these metabolites the combined values for the two structures are given,
and for simplicity we just give values for di- and trihydroxycholest-4-en-3-ones and 7α-hydroxy-3-oxocholest-4-enoic acids. Using the EADSA method 24S,25-
epoxycholesterol isomerises to 24-oxocholesterol, becomes hydrolysed to 24,25-dihydroxycholesterol and undergoes methanolysis to 3β,24-dihydroxycholest-5-ene-
25-methoxide. The total 24S,25-epoxycholesterol corresponds to the sum of the individual forms.
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(10 μg/500 μL) to 5 μM reduced the product formation by both en-
zymes. At 5 μM the concentration of 7α,(25S)26-dihydroxycholesterol
formed was below the limit of detection for incubations with either
enzyme. In 16 h incubations with 50 μM 7α-hydroxycholesterol, turn-
over of substrate by CYP3A4 (20 nM) and CYP125 (20 nM), a known
26-hydroxylase, were 3% and 7%, respectively. Negative control ex-
periments in the absence enzyme or NADPH confirmed the requirement
of enzyme and co-factor for the formation of both dihydrox-
ycholesterols. In future studies we will investigate the activities of
CYP3A enzymes towards other substrates of enhanced abundance in
Cyp27a1−/− animals. However, this preliminary study confirms
mouse CYP3A11 as a (25S)26-hydroxylase to substrates with cholest-5-
en-3β,7α-diol structure.
3.4. Sterols as nuclear receptor ligands
Sterols, including oxysterols and cholestenoic acids, are known li-
gands to nuclear receptors, including the LXRs, FXR, PXR, (also known
as the steroid xenobiotic receptor, SXR) and VDR [18,19,24,58–61].
Another nuclear receptor, CAR, or constitutive androstane receptor, as
the name implies, exhibits an intrinsically high transcriptional activity
and provokes activation of target gene expression in the absence of li-
gand binding, but can also be activated by cholesterol precursors [62].
Of these nuclear receptors, LXRα and β and PXR are known to be ex-
pressed in midbrain [63,64], and in previous studies we have identified
24S,25-epoxycholesterol to be a potent LXR ligand that enhances
midbrain dopamine neurogenesis in the developing midbrain and
Fig. 7. Cholestenoic acids in Cyp27a1−/− and
Cyp27a1+/+ (wt) mouse brain. Each chromato-
gram is normalised to the most intense peak at 100%
RA. Magnification factors are as indicated. The con-
centration of the indicated analyte (by Rt) is given in
the right-hand corner of each chromatogram.
Chromatograms from the oxysterol fractions treated
with cholesterol oxidase (combination of sterols with
a native 3-oxo group and those oxidised by cholesterol
oxidase to contain a 3-oxo group) are shown. The
insets show structures of generic GP derivatives.
Many cholestenoic acids elute as twin peaks corre-
sponding to syn and anti conformers. (A) 3β-
Hydroxychest-5-enoic and 3-oxocholest-4-enoic
acids, and dihydroxycholestenones and hydro-
xycholestenediones. (B) Dihydroxycholestenoic and
hydroxyoxocholestenoic acids. Abbreviations: 3β-
HCA, 3β-hydroxycholest-5-en-(25R)26-oic; 7αH,3O-
CA(25R or S), 7α-hydroxy-3-oxocholest-4-en-(25R or
S)26-oic.
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Fig. 8. Analysis of the PXR activational capa-
city of sterols and oxysterols of enhanced or
changed abundance in Cyp27a1−/− mouse.
Luciferase activity in SN4741 neural cells
transfected with (A) a PXR-responsive luci-
ferase reporter construct (PXRE) and PXR, and
(B) an LXR-responsive luciferase reporter con-
struct (LXRE) and LXRα, and stimulated for
24 h with the compounds indicated (10 μM).
Cholest-4-en-3-one and 7α,24-dihydrox-
ycholest-4-en-3-one were increased in brain but
not in plasma, 7α,12α-dihydroxycholestan-3-
one was elevated in plasma but not in brain, 7α,
(25S)26-dihydroxycholest-4-en-3-one and
7α,12α,25-tihydroxycholest-4-en-3-one are not
commercially available, while 7α-hydroxy-3-
oxocholest-4-en-(25S)26-oic is only available as
an unresolved mixture with the 25R epimer.
(25R)26-Hydroxycholesterol and desmosterol
were reduced in both brain and plasma of the
Cyp27a1−/− mouse, 7α-hydroxy-3-ox-
ocholest-4-en-(25R)26-oic acid was reduced in
plasma only.
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3β,7α-dihydroxycholest-5-en-(25R)26-oic acid, an intermediate in the
pathway from cholesterol to bile acids, to be a ligand to the LXRs which
enhances motor neuron survival in the CNS via activation of these re-
ceptors [19,63].
Some patients with CTX, characterised by deficiency in CYP27A1
and an inability to biosynthesise cholestenoic acids, present with motor
neuron disease [65], however, the Cyp27a1−/− mouse does not show
a motor neuron disease phenotype. In an attempt to explain this
anomaly, we have investigated if cholesterol metabolites of enhanced
abundance in the Cyp27a1−/− mouse are nuclear receptor ligands,
and whether they are protective towards motor neurons through acti-
vation of nuclear receptors.
Of the compounds of increased abundance in Cyp27a1−/− plasma
or brain none activated LXR or PXR in luciferase assays performed in
mouse neuronal cells, with the exception of cholest-4-en-3-one and 7α-
hydroxycholest-4-en-3-one which both activated PXR (Fig. 8A, Table
S2). Goodwin et al. also found that cholest-4-en-3-one and 7α-hydro-
xycholest-4-en-3-one both activate mouse PXR [24]. CYP3A11 in mouse
and CYP3A4 in human are both PXR target genes [24,60] and Honda
et al. have demonstrated that the activity of CYP3A enzyme is markedly
up-regulated in the Cyp27a1−/− mouse [34], while both Goodwin
et al. and Dussault et al. showed that hepatic expression of Cyp3a11 is
greatly increased in the Cyp27a1−/− mouse [24,60]. This data cou-
pled with Honda et al.'s finding that CYP3A11 is the predominant en-
zyme responsible for side-chain hydroxylations of 5β-cholestane-
3α,7α,12α-triol and 5β-cholestane-3α,7α,12α,25-tetrol in mouse liver
microsomes [34] and our data that CYP3A11 hydroxylates 7α-hydro-
xycholesterol at C-26, provides additional routes for cholesterol meta-
bolism in the Cyp27a1−/−mouse, one of which may go through (25S)
26-carboxylic acids (Fig. 1, inset ii). (25S)26-CoA thioesters, generated
from the corresponding acids, are substrates for the epimerase AMACR,
thus the (25S)26-acids can be converted to their 25R-epimers. This is
the likely explanation for the presence of both epimers in mouse
plasma. Although we did not differentiate the neuroprotective molecule
3β,7α-dihydroxycholest-5-en-(25R)26-oic acid or its 25S-epimer from
their 3-oxo metabolites in mouse brain from either the Cyp27a1−/− or
Fig. 9. Additional routes for cholesterol metabolism in the Cyp27a1−/− mouse. R=H in acids or SCoA in CoA thioesters. Where known enzymes are indicated in
bold. CYP3A11 was found in the present work to introduce a (25S)26-hydroxy group to 7α-hydroxycholesterol as indicated by underlining of the enzyme symbol.
The enzyme which converts the (25S)26-primary alcohol to a carboxylic acid is indicated as a sterol oxidase (SO). Metabolites of increased or decreased abundance in
the Cyp27a1−/− mouse are indicated by upward or downward arrow. Red arrows are used to indicate changes in plasma, blue arrows for brain. A horizontal solid
line indicates detected but not changed significantly. *, P < 0.05; ** P < 0.01; *** P < 0.001. P < 0.05 is considered significant. The low levels of di- and tri-
hydroxycholesterols and of dihydroxycholestenoic acids in brain makes it difficult to distinguish between these compounds and their 3-oxo equivalents using EADSA
as their differentiation is based on peak area difference between samples treated with and without cholesterol oxidase. Hence, for these metabolites the combined
values for the two structures are considered. The metabolites identified in brain are enclosed within the blue box. Abbreviations are as in Fig. 1.
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the wt genotype, the current study establishes a route to the formation
of the neuroprotective compound, even in the absence of CYP27A1,
through up-regulated CYP3A11 as summarised in Fig. 9. It is not known
whether CYP3A11, like CYP27A1, can oxidise primary alcohols to
carboxylic acids, so an additional sterol oxidase may be required for the
second oxidation. The additional pathway to 3β,7α-dihydroxycholest-5-
en-(25R)26-oic acid illustrated in Fig. 9 could explain the absence of a
CTX motor neuron phenotype in the Cyp27a1−/− mouse.
3.5. Effect of PXR ligands on oculomotor neurons
In our previous study of the effect of LXR ligands on oculomotor
neurons we found that the LXR ligand 3β,7α-dihydroxycholest-5-en-
(25R)26-oic acid increased the number of Islet-1 expressing neurons in
mouse primary midbrain cultures [19]. Islet-1 is a transcription factor
expressed in all postmitotic motor neurons. The increase in numbers of
Islet-1+ cells was found to be a consequence of increased neuronal
survival. According to the scheme presented in Fig. 9 we would predict
that treatment of midbrain primary cultures with a PXR ligand would
increase the synthesis of 3β,7α-dihydroxycholest-5-en-(25R)26-oic acid
through up-regulated CYP3A11 and thus increase the number of Islet-
1+ cells in culture. This is exactly what is observed for the more effi-
cacious activator of PXR, 7α-hydroxycholest-4-en-3-one (Fig. 10A & B).
This data substantiates the concept that neuroprotective compounds are
formed in the Cyp27a1−/− mouse through up-regulated CYP3A11. In
human, not all CTX patients suffer motor neuron signs, and perhaps the
existence of an additional route to the neuroprotective acid through
CYP3A4, the human equivalent of CYP3A11, may provide protection in
these patients. Future experiments will explore the importance of these
pathways in samples from CTX patients.
A further or alternative mechanism for motor neuron protection in
the Cyp27a1−/−mouse is through 3β,7α-dihydroxycholest-5-en-(25S)
26-oic acid which could have similar neuroprotective effects to its 25R-
epimer. Although the two epimers can be separated by LC following
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Fig. 10. The PXR ligand 7α-hydroxycholest-4-en-3-one increases the number of Islet-1+ oculomotor neurons in mouse E11.5 midbrain primary cultures, but 3β,7α-
dihydroxycholest-5-en-(25S)26-oic acid does not. (A) Representative Islet-1+ and Nkx6.1+ stained cell nuclei in cultures treated with vehicle, cholest-4-en-3-one or
7α-hydroxycholest-4-en-3-one. Quantitation of Islet-1+ neurons in primary cultures from E11.5 embryos treated with (B) vehicle, cholest-4-en-3-one or 7α-hy-
droxycholest-4-en-3-one, and (C) vehicle, 3β,7α-dihydroxycholest-5-en-(25R)26-oic or 3β,7α-dihydroxycholest-5-en-(25R/S)26-oic acid. * P < 0.05 vs vehicle
treatment, Mann-Whitney test.
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derivatisation, the underivatised molecules could not be resolved
chromatographically, so we investigated the effect of a commercial
mixture of the two epimers (25R:25S, 3:1, mole/mol) on the number of
Islet1+ cells in mouse primary brain cultures. While the 25R-epimer
alone increased the number of Islet1+ cells in culture, the mixture did
not (Fig. 10C), demonstrating that while 3β,7α-dihydroxycholest-5-en-
(25R)26-oic acid increases the survival of oculomotor neurons, 3β,7α-
dihydroxycholest-5-en-(25S)26-oic acid is less efficacious.
4. Conclusions
From the analysis of> 50 sterols, oxysterols and sterol-acids we can
conclude that a sterol hydroxylase other than CYP27A1, probably
CYP3A11, is responsible for the formation of the 25S-epimers of 7α,26-
dihydroxycholest-4-en-3-one, and perhaps 7α-hydroxy-3-oxcholest-4-
en-26-oic and 7α,12α-dihydroxycholest-4-en-26-oic acids and their 3β-
hydroxy-5-ene precursors in the Cyp27a1−/− mouse (Fig. 9). In this
mouse the 25S-sterol-acids dominate over their 25R-epimers, while the
reverse is true in the wt mice where CYP27A1 is active. In both geno-
types the 25S- and 25R-sterol-acids are inter-convertible in a reaction
catalysed AMACR after activation of the acids with Co-enzyme A. Thus,
in the Cyp27a1−/− mouse an additional (25S)26-hydroxylase pathway
may account for some of the primary bile acids formed in this mouse. It
has yet to be confirmed whether CYP3A11 can convert primary alcohols
to carboxylic acids in a manner similar to CYP27A1. If not, an alter-
native sterol oxidase must be responsible for this conversion in the
Cyp27a1−/− mouse. One candidate is CYP24A1 which has been
shown to catalyse similar reactions during vitamin D3 metabolism [66].
Interestingly, we also find low levels of 7α,24-dihydroxycholest-4-
en-3-one in both Cyp27a1−/− and wt mouse brain (Figs. 5C, 6). This
oxysterol has not previously been detected in brain. Its absence from
plasma indicates it is formed in brain rather than being imported from
the circulation.
The concurrent increase in plasma and brain of levels of many
oxysterols with a 7α-hydroxycholest-4-en-3-one structure is compatible
with their passage across the BBB down a concentration gradient. The
current data also supports the hypothesis of others [38] that oxysterols
imported to brain with a 7α-hydroxy or 7α-hydroxy-4-en-3-one struc-
ture are the precursors of cholesta-4,6-dien-3-ones in brain of
Cyp27a1−/− mice and also humans with a similar deficiency.
We were not able to distinguish between low levels of 3β,7α-dihy-
droxycholest-5-en-26-oic acids and their 3-oxo-4-ene equivalents in
mouse brain, but we were able to confirm their combined presence in
both Cyp27a1−/− and wt animals. The expression in brain of the
necessary enzymes to interconvert the 25R- and 25S-epimers of 3β,7α-
dihydroxycholest-5-en-26-oic acids provides a biosynthetic route to the
neuroprotective compound 3β,7α-dihydroxycholest-5-en-(25R)26-oic
acid [18,67], providing an explanation for the lack of a motor neuron
disease phenotype in the Cyp27a1−/− mouse.
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